A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
Part of paid clinical trials in Granada Hills, California.
- Sponsor
- Crystalys Therapeutics
- Study ID
- NCT07535034
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dotinurad — DRUGOver-encapsulated tablets containing active drug substance administered orally.
- Placebo — OTHERCapsules containing microcrystalline cellulose administered orally.
Study Details
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
Key Dates
- Start date
- May 8, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: DotinuradThe Treatment Period will consist of 2 consecutive parts: a 24-week period where participants will take dotinurad (Treatment Period 1) followed by a 12-week period where participants will continue to take dotinurad (Treatment Period 2).
- Experimental: Placebo + Placebo to DotinuardThe Treatment Period will consist of 2 consecutive parts: a 24-week period where participants will take placebo (Treatment Period 1) followed by a 12-week treatment period where participants will take dotinurad (Treatment Period 2).
Primary Outcome Measure
Percentage of Participants With an sUA Level <6.0 mg/dL at Week 24 [ Time Frame: Week 24 ]
Central Contacts
- Clinical Trial Lead(858) 356-4740
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Amicis Research Center | Granada Hills | California | 91344 | Pascal Dabel, MD |
| Cohen Medical Center | Thousand Oaks | California | 91360 | Shariar Cohen-Gadol, MD |
| Omega Research Group | DeBary | Florida | 32713 | Kwabena Ayesu, MD |
| Clinical Research of Central Florida | Lakeland | Florida | 33805 | Michael Gimness, MD |
| Anchor Medical Research | Miami | Florida | 33176 | Juvenal Martinez, MD |
| Panax Clinical Research | Miami | Florida | 33014 | Robert Perry, MD |
| MD Medical Research | Oxon Hill | Maryland | 20745 | Stephen Ong, MD |
| Clinical Research Institute of Michigan | Saint Clair Shores | Michigan | 48081 | Amar Majjhoo, MD |
| Revival Research Institute | Sterling Heights | Michigan | 48313 | Syed Husain, MD |
| Las Vegas Clinical Trials | Las Vegas | Nevada | 89030 | Alton Walters, MD |
| Ellipsis Research Group | Brooklyn | New York | 11215 | Jorge Serje, MD |
| Drug Trials America | Hartsdale | New York | 10530 | Michael Gerdis, MD |
| Shelby Clinical Research | Shelby | North Carolina | 28150 | Christian Martin, MD |
| Zenos Clinical Research | Dallas | Texas | 75230 | Bachar Elsaadi, MD |
| Epic Medical Research | DeSoto | Texas | 75115 | Haresh Boghara, MD |
| Pioneer Research Solutions | Houston | Texas | 77479 | Francisco Velazquez, MD |
| DM Clinical Research | Tomball | Texas | 77375 | Shaikh Ali, MD |
Find similar trials in Granada Hills, CA
Related Studies
- Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in GoutPHASE4 · Recruiting · Massachusetts General Hospital · South Birmingham, Alabama
- Study of Dapansutrile Tablets in Subjects With an Acute Gout FlarePHASE2/PHASE3 · Recruiting · Olatec Therapeutics LLC · Birmingham, Alabama
- A Study of Dotinurad Versus Allopurinol in Participants With GoutPHASE3 · Recruiting · Crystalys Therapeutics · Birmingham, Alabama
- A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)PHASE2 · Recruiting · Protalix · Little Rock, Arkansas